Bodisen Biotech (OTC BB:BBCZ)

GeoProfile
Overview
GeoResearch
Message Board
Alerts Log
GeoWire Log
Third party data
Quote
Level II
Historical Prices
Options
Profile
Financials
Charts
News
Filings
Insiders

Friday, May 18, 2012

Comments & Business Outlook

BODISEN BIOTECH, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND

OTHER COMPREHENSIVE INCOME (LOSS)


	Three Months Ended March 31,
	2012			2011
	(unaudited)			(unaudited)

Revenue	$	1,080,966		$	1,024,677

Cost of revenue		752,342			479,217

Gross profit		328,624			545,460

Operating expenses
Selling expenses		501,628			683,897
General and administrative expenses		818,609			516,610
Total operating expenses		1,320,237			1,200,507

Loss from operations		(991,613	)		(655,047	)

Non-operating income (expense):
Other income (expense)		(612	)		(229	)
Interest income		20,376			48,067
Interest expense		(11,311	)		(34,150	)
Total non-operating income		8,453			13,688

Net loss		(983,160	)		(641,359	)

Other comprehensive loss
Foreign currency translation gain		210,955			222,439
Unrealized gain (loss) on marketable equity security		2,392,029			(4,743,687	)
Total other comprehensive income (loss)		2,602,984			(4,521,248	)

Comprehensive income (loss)	$	1,619,824		$	(5,162,607	)

Weighted average shares outstanding :
Basic		21,510,250			21,510,250
Diluted		21,510,250			21,510,250

Loss per share:
Basic	$	(0.05	)	$	(0.03	)
Diluted	$	(0.05	)	$	(0.03	)

Permalink

Post a comment

Tuesday, April 17, 2012

Comments & Business Outlook

Results of Operations

Year Ended December 31, 2011 as Compared to Year Ended December 31, 2010

	Years Ended
	December 31,						Change
	2011			2010						$		%

Revenue	$	7,684,778		$	6,595,178		$	1,089,600			16.5

Cost of revenue		5,608,858			5,741,812			(132,954	)		(2.3	)

Gross profit		2,075,920			853,366			1,222,554			143.3

Operating expenses
Selling expenses		844,903			439,184			405,719			92.4
General and administrative expenses		3,491,847			4,558,294			(1,066,447	)		(23.4	)
Total operating expenses		4,336,750			4,997,478			(660,728	)		(13.2	)

Loss from operations		(2,260,830	)		(4,144,112	)		1,883,282			(45.4	)

Non-oparating income (expense):
Other income (expense)		(111,757	)		(5,641	)		(106,116	)		1,881.2
Interest income		207,962			72,216			135,746			188.0
Interest expense		(145,747	)		(92,856	)		(52,891	)		57.0
Total non-operating income(expense)		(49,542	)		(26,281	)		(23,261	)		88.5

Net loss	$	(2,310,372	)	$	(4,170,393	)	$	1,860,021			(44.6	)

Permalink

Post a comment

Sunday, December 11, 2011

Liquidity Requirements

Cash balance decreased to $948,137 as of September 30, 2011 as compared with $3,675,209 as of December 31, 2010 due to raw material costs increased significantly during the year, for the purposes of cost reduction, the Company has implemented a policy to build up a higher reserve of raw materials inventory through careful procurements. This has a negative impact on the cash balance. On November 17, 2011, the chairman issued an undertaking that the chairman will give his every endeavor and best effort to obtain necessary and adequate fundings to meet the Company’s financial obligations as and when they are required thereby warranting that the manufacturing operations of the Company will not be affected.

Permalink

Post a comment

Comments & Business Outlook

	Three Months Ended September 30,						Nine Months Ended September 30,
	2011			2010			2011			2010
	(unaudited)			(unaudited)			(unaudited)			(unaudited)

Revenue	$	1,781,006		$	2,209,724		$	4,222,293		$	5,661,715

Cost of revenue		1,378,949			1,559,565			2,417,093			4,224,164

Gross profit		402,057			650,159			1,805,200			1,437,551

Operating expenses
Selling expenses		87,935			25,835			802,109			372,021
General and administrative expenses		1,127,763			956,675			2,176,280			2,418,410
Total operating expenses		1,215,698			982,510			2,978,389			2,790,431

Loss from operations		(813,641	)		(332,351	)		(1,173,189	)		(1,352,880	)

Non-operating income (expense):
Other income (expense)		(349	)		(61,531	)		(2,858	)		(81,372	)
Interest income		61,181			5,826			167,907			13,712
Interest expense		(39,798	)		(40,438	)		(111,390	)		(61,561	)
Loss on disposal of property and equipment		-			(10,297	)		-			(10,297	)
Total non-operating income		21,034			(106,440	)		53,659			(139,518	)

Net loss		(792,607	)		(438,791	)		(1,119,530	)		(1,492,398	)

Other comprehensive income (loss)
Foreign currency translation gain (loss)		379,542			653,271			1,050,200			821,389
Unrealized gain (loss) on marketable equity security		(1,029,481	)		201,859			(7,771,572	)		1,312,083

Comprehensive income (loss)	$	(1,442,546	)	$	416,339		$	(7,840,902	)	$	641,074

Weighted average shares outstanding :
Basic		21,510,250			18,710,250			21,510,250			18,710,250
Diluted		21,510,250			18,710,250			21,510,250			18,710,250

Loss per share:
Basic	$	(0.04	)	$	(0.02	)	$	(0.05	)	$	(0.08	)
Diluted	$	(0.04	)	$	(0.02	)	$	(0.05	)	$	(0.08

The decrease in revenue is primarily attributable to a raise in commodity prices, the purchasing power of farmers declining, coupled with excessive rainfall in the summer months that led to flooding in some regions resulting in a reduced demand for crop production and fertilizer.

Permalink

Post a comment

Tuesday, August 16, 2011

Comments & Business Outlook

BODISEN BIOTECH, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND

OTHER COMPREHENSIVE INCOME (LOSS)

	Three Months Ended June 30,						Six Months Ended June 30,
	2011			2010			2011			2010
	(unaudited)			(unaudited)			(unaudited)			(unaudited)

Net revenue	$	1,416,610		$	1,913,649		$	2,441,287		$	3,451,991

Cost of revenue		558,927			1,854,716			1,038,144			2,664,599

Gross profit		857,683			58,933			1,403,143			787,392

Operating expenses
Selling expenses		30,277			204,772			714,174			346,186
General and administrative expenses		531,907			713,751			1,048,517			1,461,735
Total operating expenses		562,184			918,523			1,762,691			1,807,921

Income (loss) from operations		295,499			(859,590	)		(359,548	)		(1,020,529	)

Non-operating income (expense):
Other income (expense)		(2,280	)		(19,227	)		(2,509	)		(19,841	)
Interest income		58,659			4,718			106,726			7,886
Interest expense		(37,442	)		(20,463	)		(71,592	)		(21,123	)
Total non-operating income		18,937			(34,972	)		32,625			(33,078	)

Net income (loss)		314,436			(894,562	)		(326,923	)		(1,053,607	)

Other comprehensive income (loss)
Foreign currency translation gain (loss)		448,219			168,197			670,658			168,118
Unrealized gain (loss) on marketable equity security		(1,998,404	)		2,240,634			(6,742,091	)		1,110,224

Comprehensive income (loss)	$	(1,235,749	)	$	1,514,269		$	(6,398,356	)	$	224,735

Weighted average shares outstanding :
Basic		21,510,250			18,710,250			21,510,250			18,710,250
Diluted		21,510,250			18,710,250			21,510,250			18,710,250

Earnings (loss) per share:
Basic	$	0.01		$	(0.05	)	$	(0.02	)	$	(0.06	)
Diluted	$	0.01		$	(0.05	)	$	(0.02	)	$	(0.06	)

Permalink

Post a comment

Friday, April 15, 2011

Comments & Business Outlook

BODISEN BIOTECH, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND

OTHER COMPREHENSIVE INCOME (LOSS)

	2010			2009
				(as restated)

Net revenue	$	6,595,178		$	5,217,277

Cost of revenue		5,741,812			3,857,921

Gross profit		853,366			1,359,356

Operating expenses
Selling expenses		439,184			151,756
General and administrative expenses		4,558,294			2,060,553
Writedown of assets		-			104,283
Total operating expenses		4,997,478			2,316,592

Loss from operations		(4,144,112	)		(957,236	)

Non-operating income (expense):
Other income (expense)		(5,461	)		(2,178	)
Interest income		72,216			3,275
Interest expense		(92,956	)		(336	)
Gain on sale of investment, net		-			842,145
Equity income in investment		-			484,794
Total non-operating income (expense)		(26,201	)		1,327,700

Income (loss) before provision for income taxes		(4,170,313	)		370,464

Provision (benefit) for income taxes		-			-

Net income (loss)		(4,170,313	)		370,464

Other comprehensive income
Foreign currency translation gain		1,146,420			10,745
Unrealized gain on marketable equity security		605,577			2,021,600

Comprehensive income (loss)	$	(2,418,316	)	$	2,402,809

Weighted average shares outstanding :
Basic		18,825,318			18,710,250
Diluted		18,825,318			18,710,250

Earnings per share:
Basic	$	(0.22	)	$	0.02
Diluted	$	(0.22	)	$	0.02

Permalink

Post a comment

Monday, November 22, 2010

Comments & Business Outlook

	Three Months Ended September 30,							Nine Months Ended September 30,
		2010			2009				2010			2009
		(unaudited)			(unaudited)				(unaudited)			(unaudited)
					(as restated)							(as restated)
Net revenue		$	2,209,724		$	56,090			$	5,661,715		$	3,246,456

Cost of revenue			1,559,565			503,530				4,224,164			2,720,245

Gross profit (loss)			650,159			(447,440	)			1,437,551			526,211

Operating expenses
Selling expenses			25,835			15,816				372,021			42,934
General and administrative expenses			956,675			494,744				2,418,410			794,886
Writedown of assets			-			-							104,254
Total operating expenses			982,510			510,560				2,790,431			942,074

Loss from operations			(332,351	)		(958,000	)			(1,352,880	)		(415,863	)

Non-operating income (expense):
Other income (expense)			(61,531	)		(503	)			(81,372	)		(1,787	)
Interest income			5,826			82				13,712			396
Interest expense			(40,438	)		(60	)			(61,561	)		(208	)
Loss on disposal of property and equipment			(10,297	)		-				(10,297	)		-
Loss on the sale of investment			-			(29	)			-			(211,639	)
Equity income in investment			-			177,826				-			484,728
Total non-operating income (expense)			(106,440	)		177,316				(139,518	)		271,490

Loss before provision for income taxes			(438,791	)		(780,684	)			(1,492,398	)		(144,373	)

Provision (benefit) for income taxes			-			-							-

Net loss			(438,791	)		(780,684	)			(1,492,398	)		(144,373	)

Other comprehensive income (loss)
Foreign currency translation gain			653,271			55,167				821,389			259
Unrealized gain (loss) on marketable equity security			201,859			(7,161,275	)			1,312,083			(2,270,145	)

Comprehensive loss		$	416,339		$	(7,886,792	)		$	641,074		$	(2,414,259	)

Weighted average shares outstanding :
Basic			18,710,250			18,710,250				18,710,250			18,710,250
Diluted			18,710,250			18,710,250				18,710,250			18,710,250

Loss per share:
Basic		$	(0.02	)	$	(0.04	)		$	(0.08	)	$	(0.01	)
Diluted		$	(0.02	)	$	(0.04	)		$	(0.08	)	$	(0.01	)

Permalink

Post a comment

Thursday, October 28, 2010

Investor Alert

The Company changed its revenue recognition policy to the cost recovery method as the Company does not believe that collection is reasonably assured. Under the cost recovery method, no profit is recognized until cash payments exceed the cost of the goods sold and the Company records deferred revenue which is the gross profit that has not been realized. As a result of the change in the revenue recognition policy, the Company is filing an amendment to the Form 10-Q that was originally filed with the Securities and Exchange Commission on May 14, 2010.

Permalink

Post a comment

Wednesday, April 30, 2008

Research

Seems to be involved in litigation issues that may have affected credibility. Also 2007 results have been below 2006 due to : "abnormally cold spring time in Shaanxi and the massive flooding we experienced in August".

"This has been a difficult year for the Company with the impact of the abnormally cold spring time in Shaanxi and the massive flooding we experienced in August, together with the impact of the AMEX de-listing. However, the business continues to trade profitably and we have a strong balance sheet. The organic fertilizer market in China is still in its infancy and there remains an enormous market opportunity. Accordingly, the Company has continued confidence in the future of the business."

source ( press 9/28/07)

need to take a wait and see stance and see if the aforementioned problems are are one time events. before making any decision.

Permalink

Post a comment